Jiangsu Hengrui Medicine Co., Ltd. and The University of Texas MD Anderson Cancer Center (MD Anderson) have entered into a research agreement to advance cancer treatment. The 3-year agreement for translational research brings together the scientific and clinical capabilities of MD Anderson and Jiangsu Hengrui Medicine to develop rational combination therapies and personalized medicines as well as to identify new treatment opportunities, especially in the field of immuno-oncology.